MedPath

Takeda Pharmaceutical Company Ltd

🇸🇪Sweden
Ownership
-
Established
1925-01-01
Employees
-
Market Cap
$47.5B
Website
http://www.takeda.co.jp/
Clinical Trials
Related News

Human Pharmacology Trial of Calcium-vitamin D3 Tablet in Healthy Participants

Phase 1
Completed
Conditions
Calcium Deficiency
Vitamin D Deficiency
Interventions
Drug: Calcium 500 mg and Vitamin D3 800 IU
Other: Low calcium meals
First Posted Date
2012-07-12
Last Posted Date
2013-10-18
Lead Sponsor
Takeda
Target Recruit Count
55
Registration Number
NCT01639222

Cohort Study of Pioglitazone and Bladder Cancer in Patients With Type II Diabetes

Completed
Conditions
Bladder Cancer
Diabetes
Interventions
Drug: Pioglitazone
First Posted Date
2012-07-11
Last Posted Date
2018-03-07
Lead Sponsor
Takeda
Target Recruit Count
193099
Registration Number
NCT01637935

Double-blind Comparative Study of SYR-472

Phase 3
Completed
Conditions
Diabetes Mellitus
Interventions
Drug: SYR-472
Drug: Alogliptin 25 mg
Drug: Placebo
First Posted Date
2012-06-29
Last Posted Date
2023-12-11
Lead Sponsor
Takeda
Target Recruit Count
245
Registration Number
NCT01632007

A Randomized, Double-Blind, Multicenter Study to Evaluate the Acid-inhibitory and Dose-response Efficacy of TAK-438 (20 mg, 40 mg) in Patients With Proton Pump Inhibitor (PPI) - Resistant Erosive Esophagitis

Phase 3
Completed
Conditions
Erosive Esophagitis
Interventions
Drug: TAK-438
First Posted Date
2012-06-28
Last Posted Date
2014-02-10
Lead Sponsor
Takeda
Target Recruit Count
19
Registration Number
NCT01630746

Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease

Phase 3
Terminated
Conditions
Type 2 Diabetes
Cardiovascular Disease
Interventions
Drug: TAK-875
Drug: TAK-875 Placebo
First Posted Date
2012-06-01
Last Posted Date
2015-10-19
Lead Sponsor
Takeda
Target Recruit Count
3207
Registration Number
NCT01609582

Norovirus Bivalent-Vaccine Efficacy Study

Phase 1
Completed
Conditions
Prevention From Norovirus Infection
Interventions
Biological: Norovirus Bivalent Vaccine
Biological: Saline Comparator
First Posted Date
2012-05-31
Last Posted Date
2019-01-09
Lead Sponsor
Takeda
Target Recruit Count
132
Registration Number
NCT01609257
Locations
🇺🇸

University of Rochester, Rochester, New York, United States

🇺🇸

Cincinnati Childrens Hospital Medical Center, Cincinnati, Ohio, United States

🇺🇸

Emory University, Atlanta, Georgia, United States

and more 2 locations

Drug Interaction Study of Colchicine and Theophylline

Phase 4
Completed
Conditions
Healthy
Interventions
Drug: colchicine
Drug: theophylline
First Posted Date
2012-05-17
Last Posted Date
2013-06-17
Lead Sponsor
Takeda
Target Recruit Count
30
Registration Number
NCT01601132
Locations
🇺🇸

Worlwide Clinical Trials Drug Development Solutions, Clinical Research Services, San Antonio, Texas, United States

Double Blind Comparative Study of TAK-875

Phase 3
Completed
Conditions
Diabetic Patients
Interventions
Drug: TAK-875
Drug: Placebo
Drug: Glimepiride
First Posted Date
2012-04-26
Last Posted Date
2013-04-16
Lead Sponsor
Takeda
Target Recruit Count
80
Registration Number
NCT01585792

Efficacy and Safety of Actovegin in Post-stroke Cognitive Impairment (PSCI)

Phase 3
Completed
Conditions
Post-Stroke Cognitive Impairment (PSCI)
Interventions
Drug: Actovegin
Drug: Placebo
First Posted Date
2012-04-23
Last Posted Date
2016-02-22
Lead Sponsor
Takeda
Target Recruit Count
503
Registration Number
NCT01582854
Locations
🇷🇺

Nycomed Investigational Site, Tomsk, Russian Federation

A Unblinded Study of TAK-438 (20 mg) for Prevention of Recurrence of Gastric or Duodenal Ulcer During Long-Term Non-Steroid Anti-Inflammatory Drug (NSAID) Therapy

Phase 3
Completed
Conditions
Gastric Ulcer
Duodenal Ulcer
Interventions
Drug: TAK-438
First Posted Date
2012-04-02
Last Posted Date
2014-02-10
Lead Sponsor
Takeda
Target Recruit Count
30
Registration Number
NCT01568385
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy